Clinical Trial

Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 15, 2022 (before its estimated December 2024 completion). Its status may not reflect the trial's current state.
Summary
This study is a prospective single-arm phase II study to evaluate the efficacy and safety of Pemigatinib in the advanced gastrointestinal cancer with FGFR 1-3 alterations and failed standard therapy.
Trial Details
NCT Number NCT05651672
Lead Sponsor Tianjin Medical University Cancer Institute and Hospital
Conditions Gastrointestinal Cancer
Enrollment 100 participants
Start Date 2022-12-02
Primary Completion 2024-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2022-12-15